A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
Conclusions Although the TAS-114/S-1 combination improved the response rate, this did not translate into improvements in PFS.Clinical Trial Registration No. NCT02855125 (ClinicalTrials.gov) registered on 4 August 2016.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Clinical Trials | Drugs & Pharmacology | Investigational New Drugs | Lung Cancer | Non-Small Cell Lung Cancer | Skin | Study | Toxicology